We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
Read MoreHide Full Article
Viatris (VTRS - Free Report) closed at $10.99 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's 0.63% loss on the day. Elsewhere, the Dow lost 0.19%, while the tech-heavy Nasdaq lost 0.34%.
Coming into today, shares of the generic drugmaker had gained 10.15% in the past month. In that same time, the Medical sector gained 5.54%, while the S&P 500 gained 6.02%.
Wall Street will be looking for positivity from Viatris as it approaches its next earnings report date. In that report, analysts expect Viatris to post earnings of $0.84 per share. This would mark a year-over-year decline of 8.7%. Our most recent consensus estimate is calling for quarterly revenue of $4.28 billion, down 3.37% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.46 per share and revenue of $17.36 billion. These totals would mark changes of -6.49% and -2.92%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.1% lower. Viatris is holding a Zacks Rank of #5 (Strong Sell) right now.
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 3.23 right now. Its industry sports an average Forward P/E of 25.09, so we one might conclude that Viatris is trading at a discount comparatively.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 176, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Viatris (VTRS) Dips More Than Broader Markets: What You Should Know
Viatris (VTRS - Free Report) closed at $10.99 in the latest trading session, marking a -1.7% move from the prior day. This change lagged the S&P 500's 0.63% loss on the day. Elsewhere, the Dow lost 0.19%, while the tech-heavy Nasdaq lost 0.34%.
Coming into today, shares of the generic drugmaker had gained 10.15% in the past month. In that same time, the Medical sector gained 5.54%, while the S&P 500 gained 6.02%.
Wall Street will be looking for positivity from Viatris as it approaches its next earnings report date. In that report, analysts expect Viatris to post earnings of $0.84 per share. This would mark a year-over-year decline of 8.7%. Our most recent consensus estimate is calling for quarterly revenue of $4.28 billion, down 3.37% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $3.46 per share and revenue of $17.36 billion. These totals would mark changes of -6.49% and -2.92%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Viatris. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 6.1% lower. Viatris is holding a Zacks Rank of #5 (Strong Sell) right now.
Valuation is also important, so investors should note that Viatris has a Forward P/E ratio of 3.23 right now. Its industry sports an average Forward P/E of 25.09, so we one might conclude that Viatris is trading at a discount comparatively.
The Medical Services industry is part of the Medical sector. This group has a Zacks Industry Rank of 176, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.